[{"trial_metadata": {"citation": "Proc (Bayl Univ Med Cent) 2006;19:281-284", "drug_name": "Exenatide (Byetta)", "phase": "Phase III", "indication": "Type 2 Diabetes Mellitus", "numeric_trial_duration": 30, "trial_duration": "30 weeks", "safety_population_definition": "All patients who received one dose of medication", "NCT Number": "N/A", "Sponsor": "Amylin Pharmaceuticals, Inc.", "route of adminstration": "Subcutaneous"}, "baseline_table": [], "ae_events": [{"AE_label_raw": "Nausea", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo", "total_n": 483, "arm_role": "control", "n_with_event": 87, "percent_with_event": 18}}, {"AE_label_raw": "Nausea", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide", "total_n": 963, "arm_role": "treatment", "n_with_event": 423, "percent_with_event": 44}}, {"AE_label_raw": "Vomiting", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo", "total_n": 483, "arm_role": "control", "n_with_event": 19, "percent_with_event": 4}}, {"AE_label_raw": "Vomiting", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide", "total_n": 963, "arm_role": "treatment", "n_with_event": 125, "percent_with_event": 13}}, {"AE_label_raw": "Diarrhea", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo", "total_n": 483, "arm_role": "control", "n_with_event": 29, "percent_with_event": 6}}, {"AE_label_raw": "Diarrhea", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide", "total_n": 963, "arm_role": "treatment", "n_with_event": 125, "percent_with_event": 13}}, {"AE_label_raw": "Feeling jittery", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo", "total_n": 483, "arm_role": "control", "n_with_event": 19, "percent_with_event": 4}}, {"AE_label_raw": "Feeling jittery", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide", "total_n": 963, "arm_role": "treatment", "n_with_event": 87, "percent_with_event": 9}}, {"AE_label_raw": "Dizziness", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo", "total_n": 483, "arm_role": "control", "n_with_event": 29, "percent_with_event": 6}}, {"AE_label_raw": "Dizziness", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide", "total_n": 963, "arm_role": "treatment", "n_with_event": 87, "percent_with_event": 9}}, {"AE_label_raw": "Headache", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo", "total_n": 483, "arm_role": "control", "n_with_event": 29, "percent_with_event": 6}}, {"AE_label_raw": "Headache", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide", "total_n": 963, "arm_role": "treatment", "n_with_event": 87, "percent_with_event": 9}}, {"AE_label_raw": "Dyspepsia", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo", "total_n": 483, "arm_role": "control", "n_with_event": 14, "percent_with_event": 3}}, {"AE_label_raw": "Dyspepsia", "event_category": "Frequent treatment-emergent adverse events (\u22655% incidence and greater incidence with Byetta treatment) excluding hypoglycemia", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide", "total_n": 963, "arm_role": "treatment", "n_with_event": 58, "percent_with_event": 6}}]}]